Styx Biotechnologies

Styx Biotechnologies is a San Diego-based precision oncology company focused on developing next-generation antibody-drug conjugates (ADCs) for solid tumors with high unmet medical needs, including liver, gastric, and rare cancers. The company leverages its proprietary AI-assisted AbRefine algorithm for antibody humanization and optimization, alongside a dual-payload ADC platform designed to address tumor heterogeneity, resistance, and delivery challenges. Styx maintains strategic access to a broad panel of monoclonal antibodies and has secured exclusive worldwide therapeutic licensing rights to support its pipeline. In September 2026, Styx entered into a strategic agreement with ZoeNCure Therapeutics to accelerate its lead ADC programs, including STX-ADC02, into first-in-human clinical trials.